News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
Press
Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
July 17, 2023
Endpoints News
Read Now
News
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
Press
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
News
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June
May 22, 2023
Read Now
News
Scribe signs another big pharma deal
May 19, 2023
Evaluate
Read Now
Press
Scribe signs another big pharma deal
May 19, 2023
Evaluate
Read Now
News
Scribe Inks CRISPR Gene-Editing Deal with Prevail
May 19, 2023
Bloomberg
Read Now
Press
Scribe Inks CRISPR Gene-Editing Deal with Prevail
May 19, 2023
Bloomberg
Read Now
News
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now
Press
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2023
Read Now